0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Chemotherapy Induced Peripheral Neuropathy (CIPN) - Pipeline Insight, 2019
Published Date: February 2019
|
Report Code: DELV-Pipe-11
Home | Market Reports | Health | Health Conditions | Pain Management
Global Chemotherapy Induced Peripheral Neuropathy Pipeline Insight 2019

Chemotherapy Induced Peripheral Neuropathy (CIPN) - Pipeline Insight, 2019

Code: DELV-Pipe-11
Report
February 2019
90 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

"Chemotherapy Induced Peripheral Neuropathy (CIPN) - Pipeline Insight, 2019” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chemotherapy Induced Peripheral Neuropathy (CIPN) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Chemotherapy Induced Peripheral Neuropathy (CIPN)
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Chemotherapy Induced Peripheral Neuropathy (CIPN)
The report assesses the active Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Chemotherapy Induced Peripheral Neuropathy (CIPN)
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Chemotherapy Induced Peripheral Neuropathy (CIPN)
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Chemotherapy Induced Peripheral Neuropathy (CIPN)
• The report also covers the dormant and discontinued pipeline projects related to the Chemotherapy Induced Peripheral Neuropathy (CIPN)

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Chemotherapy Induced Peripheral Neuropathy (CIPN) to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Chemotherapy Induced Peripheral Neuropathy (CIPN) therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

1. Report Introduction
2. Chemotherapy Induced Peripheral Neuropathy (CIPN) Overview
3. Pipeline Therapeutics
• An Overview of Pipeline Products for Chemotherapy Induced Peripheral Neuropathy (CIPN)
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
7. Therapeutic Assessment
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List of Tables

Table 1: Total Products for Chemotherapy Induced Peripheral Neuropathy (CIPN)
Table 2: Products in Clinical Stage
Table 3: Products in Non-clinical Stage
Table 4: Assessment by Route of Administration
Table 5: Assessment by Stage and Route of Administration
Table 6: Assessment by Molecule Type
Table 7: Assessment by Stage and Molecule Type
Table 8: Inactive Products

List of Figures

Figure 1: Total Products for Chemotherapy Induced Peripheral Neuropathy (CIPN)
Figure 2: Products in Clinical Stage
Figure 3: Products in Non-clinical Stage
Figure 4: Assessment by Route of Administration
Figure 5: Assessment by Stage and Route of Administration
Figure 6: Assessment by Molecule Type
Figure 7: Assessment by Stage and Molecule Type
Figure 8: Inactive Products

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$1500
This license allows only one user to access the PDF.

Electronic (PDF)
$3000
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$4500
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Novocure

RELATED REPORTS

China Antipyretic Analgesics Market Report Forecast 2021 2027
China Antipyretic Analgesics Market Report & Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-20T5723
Sat Oct 02 00:00:00 UTC 2021

Add to Cart

Global and United States Knee Pain Management Market Size Status and Forecast 2021 2027
Global and United States Knee Pain Management Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-30J6482
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and Japan Bone Pain Treatment Market Size Status and Forecast 2021 2027
Global and Japan Bone Pain Treatment Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-6I7338
Tue Aug 24 00:00:00 UTC 2021

Add to Cart

Global Ketoprofen Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Ketoprofen Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Top 3 companies occupied about 83 market share.Market Analysis and Insights Global Ketoprofen MarketIn 2020 the global Ketoprofen market size was US 34 million and it is expected to reach US 39 million by the end of 2027 with a CAGR of 1.9 during 20212027.Global Ketoprofen Scope and Market SizeKetoprofen market is segmented by region by country company t.

120 Pages
Type: Report
Code: QYRE-Auto-2K2665
Fri Aug 13 00:00:00 UTC 2021

Add to Cart